- Home
- ESEA vs AUTL Comparison
ESEA vs AUTL Comparison
Compare ESEA & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESEA | AUTL |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | Greece | United Kingdom |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.2M | 407.2M |
| IPO Year | 2005 | 2025 |
Fundamental Metrics
Financial Performance| Metric | ESEA | AUTL |
|---|---|---|
| Price | $68.59 | $1.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $62.00 | $8.50 |
| AVG Volume (30 Days) | 60.2K | ★ 1.2M |
| Earning Date | 06-17-2026 | 05-14-2026 |
| Dividend Yield | ★ 4.24% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | $1.74 | $80.32 |
| Revenue Next Year | $1.07 | $53.96 |
| P/E Ratio | $3.39 | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $33.88 | $1.15 |
| 52 Week High | $74.75 | $2.70 |
Technical Indicators
Market Signals| Indicator | ESEA | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 49.82 | 56.28 |
| Support Level | $51.63 | $1.22 |
| Resistance Level | $72.82 | $1.69 |
| Average True Range (ATR) | 2.95 | 0.08 |
| MACD | -0.23 | -0.00 |
| Stochastic Oscillator | 24.82 | 57.63 |
Price Performance
Historical ComparisonAbout ESEA Euroseas Ltd. (Marshall Islands)
Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes, providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.